572 related articles for article (PubMed ID: 27166358)
1. Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy.
Bhoj VG; Arhontoulis D; Wertheim G; Capobianchi J; Callahan CA; Ellebrecht CT; Obstfeld AE; Lacey SF; Melenhorst JJ; Nazimuddin F; Hwang WT; Maude SL; Wasik MA; Bagg A; Schuster S; Feldman MD; Porter DL; Grupp SA; June CH; Milone MC
Blood; 2016 Jul; 128(3):360-70. PubMed ID: 27166358
[TBL] [Abstract][Full Text] [Related]
2. Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy.
Hill JA; Krantz EM; Hay KA; Dasgupta S; Stevens-Ayers T; Bender Ignacio RA; Bar M; Maalouf J; Cherian S; Chen X; Pepper G; Riddell SR; Maloney DG; Boeckh MJ; Turtle CJ
Blood Adv; 2019 Nov; 3(22):3590-3601. PubMed ID: 31743392
[TBL] [Abstract][Full Text] [Related]
3. Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice.
DiLillo DJ; Hamaguchi Y; Ueda Y; Yang K; Uchida J; Haas KM; Kelsoe G; Tedder TF
J Immunol; 2008 Jan; 180(1):361-71. PubMed ID: 18097037
[TBL] [Abstract][Full Text] [Related]
4. Anti-CD19 chimeric antigen receptor-modified T cells for B-cell malignancies: a systematic review of efficacy and safety in clinical trials.
Zhu Y; Tan Y; Ou R; Zhong Q; Zheng L; Du Y; Zhang Q; Huang J
Eur J Haematol; 2016 Apr; 96(4):389-96. PubMed ID: 26115358
[TBL] [Abstract][Full Text] [Related]
5. CD20-CD19 Bispecific CAR T Cells for the Treatment of B-Cell Malignancies.
Martyniszyn A; Krahl AC; André MC; Hombach AA; Abken H
Hum Gene Ther; 2017 Dec; 28(12):1147-1157. PubMed ID: 29207878
[TBL] [Abstract][Full Text] [Related]
6. Antibodies against vaccine-preventable infections after CAR-T cell therapy for B cell malignancies.
Walti CS; Krantz EM; Maalouf J; Boonyaratanakornkit J; Keane-Candib J; Joncas-Schronce L; Stevens-Ayers T; Dasgupta S; Taylor JJ; Hirayama AV; Bar M; Gardner RA; Cowan AJ; Green DJ; Boeckh MJ; Maloney DG; Turtle CJ; Hill JA
JCI Insight; 2021 Jun; 6(11):. PubMed ID: 33914708
[TBL] [Abstract][Full Text] [Related]
7. Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.
Garfall AL; Stadtmauer EA; Hwang WT; Lacey SF; Melenhorst JJ; Krevvata M; Carroll MP; Matsui WH; Wang Q; Dhodapkar MV; Dhodapkar K; Das R; Vogl DT; Weiss BM; Cohen AD; Mangan PA; Ayers EC; Nunez-Cruz S; Kulikovskaya I; Davis MM; Lamontagne A; Dengel K; Kerr ND; Young RM; Siegel DL; Levine BL; Milone MC; Maus MV; June CH
JCI Insight; 2018 Apr; 3(8):. PubMed ID: 29669947
[TBL] [Abstract][Full Text] [Related]
8. T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells.
Vera J; Savoldo B; Vigouroux S; Biagi E; Pule M; Rossig C; Wu J; Heslop HE; Rooney CM; Brenner MK; Dotti G
Blood; 2006 Dec; 108(12):3890-7. PubMed ID: 16926291
[TBL] [Abstract][Full Text] [Related]
9. Lasting antibody responses are mediated by a combination of newly formed and established bone marrow plasma cells drawn from clonally distinct precursors.
Chernova I; Jones DD; Wilmore JR; Bortnick A; Yucel M; Hershberg U; Allman D
J Immunol; 2014 Nov; 193(10):4971-9. PubMed ID: 25326027
[TBL] [Abstract][Full Text] [Related]
10. Long-Lived Plasma Cells Are Contained within the CD19(-)CD38(hi)CD138(+) Subset in Human Bone Marrow.
Halliley JL; Tipton CM; Liesveld J; Rosenberg AF; Darce J; Gregoretti IV; Popova L; Kaminiski D; Fucile CF; Albizua I; Kyu S; Chiang KY; Bradley KT; Burack R; Slifka M; Hammarlund E; Wu H; Zhao L; Walsh EE; Falsey AR; Randall TD; Cheung WC; Sanz I; Lee FE
Immunity; 2015 Jul; 43(1):132-45. PubMed ID: 26187412
[TBL] [Abstract][Full Text] [Related]
11. Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.
Schuster SJ; Svoboda J; Chong EA; Nasta SD; Mato AR; Anak Ö; Brogdon JL; Pruteanu-Malinici I; Bhoj V; Landsburg D; Wasik M; Levine BL; Lacey SF; Melenhorst JJ; Porter DL; June CH
N Engl J Med; 2017 Dec; 377(26):2545-2554. PubMed ID: 29226764
[TBL] [Abstract][Full Text] [Related]
12. Bone marrow derived long-lived plasma cell phenotypes are heterogeneous and can change in culture.
Mujtahedi SS; Yigitbilek F; Benavides X; Merzkani MA; Ozdogan E; Abozied O; Moore NA; Park WD; Stegall MD
Transpl Immunol; 2022 Dec; 75():101726. PubMed ID: 36183942
[TBL] [Abstract][Full Text] [Related]
13. Limited humoral immunoglobulin E memory influences serum immunoglobulin E levels in blood.
Achatz-Straussberger G; Zaborsky N; Königsberger S; Feichtner S; Lenz S; Peckl-Schmid D; Lamers M; Achatz G
Clin Exp Allergy; 2009 Sep; 39(9):1307-13. PubMed ID: 19489847
[TBL] [Abstract][Full Text] [Related]
14. Activity of Anti-CD19 Chimeric Antigen Receptor T Cells Against B Cell Lymphoma Is Enhanced by Antibody-Targeted Interferon-Alpha.
Young PA; Yamada RE; Trinh KR; Vasuthasawat A; De Oliveira S; Yamada DH; Morrison SL; Timmerman JM
J Interferon Cytokine Res; 2018 Jun; 38(6):239-254. PubMed ID: 29920129
[TBL] [Abstract][Full Text] [Related]
15. Sequential treatment with aT19 cells generates memory CAR-T cells and prolongs the lifespan of Raji-B-NDG mice.
Chen R; Wang M; Liu Q; Wu J; Huang W; Li X; Du B; Xu Q; Duan J; Jiao S; Lee HS; Jung NC; Lee JH; Wang Y; Wang Y
Cancer Lett; 2020 Jan; 469():162-172. PubMed ID: 31634527
[TBL] [Abstract][Full Text] [Related]
16. Long-lived plasma cells are generated in mucosal immune responses and contribute to the bone marrow plasma cell pool in mice.
Lemke A; Kraft M; Roth K; Riedel R; Lammerding D; Hauser AE
Mucosal Immunol; 2016 Jan; 9(1):83-97. PubMed ID: 25943272
[TBL] [Abstract][Full Text] [Related]
17. Survival of long-lived plasma cells is independent of antigen.
Manz RA; Löhning M; Cassese G; Thiel A; Radbruch A
Int Immunol; 1998 Nov; 10(11):1703-11. PubMed ID: 9846699
[TBL] [Abstract][Full Text] [Related]
18. Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy.
Kochenderfer JN; Somerville RPT; Lu T; Yang JC; Sherry RM; Feldman SA; McIntyre L; Bot A; Rossi J; Lam N; Rosenberg SA
Mol Ther; 2017 Oct; 25(10):2245-2253. PubMed ID: 28803861
[TBL] [Abstract][Full Text] [Related]
19. Short-lived and long-lived bone marrow plasma cells are derived from a novel precursor population.
O'Connor BP; Cascalho M; Noelle RJ
J Exp Med; 2002 Mar; 195(6):737-45. PubMed ID: 11901199
[TBL] [Abstract][Full Text] [Related]
20. Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma.
Mihara K; Yanagihara K; Takigahira M; Kitanaka A; Imai C; Bhattacharyya J; Kubo T; Takei Y; Yasunaga S; Takihara Y; Kimura A
Br J Haematol; 2010 Oct; 151(1):37-46. PubMed ID: 20678160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
